Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.

XyloCor has dosed the first subject in the multi-centre, randomised Phase IIb EXACT-2 trial to assess the gene therapy candidate, XC001.

UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.

US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II trial.

Artificial intelligence (AI) should soon be taking a greater role in areas including patient recruitment and in building efficiencies around data quality.